DART
Alpha-radiotherapy for Precision Radiation Oncology
Heads:
Pr. Désirée Déandréis; Pr. Eric Deutsch
Objectives
DART is the first integrated European platform dedicated to alpha therapy, designed to accelerate the development of this emerging therapeutic modality from the preclinical stage through to clinical application. Its bench-to-bedside approach is supported by a preclinical and clinical center of excellence, combined with the development of advanced three-level dosimetry powered by artificial intelligence modeling. This integrated framework aims to optimize treatment planning, improve therapeutic efficacy, and facilitate the translation of alpha-emitting radiopharmaceuticals into clinical practice.
Operator (s)
Technology and expertises
DART provides industrial partners with fast-track, secure access to alpha-therapy development through three interconnected pillars.
1. A GLP-certified preclinical radiopharmaceutical facility combining regulatory compliance with access to the unique expertise available at the Gustave Roussy site.
2. A Centre of Clinical Excellence supported by Gustave Roussy’s Clinical Research Platform and Department of Therapeutic Innovation (DITEP), dedicated to the development of alpha-emitting therapies from Phase 0 to Phase III clinical trials.
3. A translational research platform in medical physics, radiobiology, pharmacokinetics, and immunology bringing together multimodal imaging, advanced dosimetry, artificial intelligence, and molecular profiling within a single infrastructure to support the full development pathway of alpha-therapy.
Services and activities
The GLP Preclinical Radiopharmaceutical Facility
GLP-certified preclinical studies.
Sophisticated mouse models, including syngeneic and patient-derived xenograft (PDX) models.
Expertise in immunology, particularly in understanding the interactions between alpha-therapy and the immune system.
Advanced three-level dosimetry for treatment regimen optimization.
In-depth molecular characterization capabilities.
The Clinical Centre of Excellence
Early-phase clinical trials, from Phase 0 to Phase I–II.
Advanced personalized dosimetry to optimize therapeutic efficacy.
Theranostic imaging for real-time treatment monitoring.
On-site radioligand labeling through the hospital pharmacy extension.
Expertise in combination therapies.
Translational Lab in Pharmacokinetics, Medical Physics and Radiobiology
Integrated expertise spanning medical physics, radiobiology, pharmacokinetics, and immunology.
Multimodal imaging infrastructure supporting translational research.
Advanced dosimetry and AI-based modeling capabilities.
Biomarker discovery and molecular profiling platforms.